GleamWall
中文EN

OMER OMEROS CORP

Pharmaceutical Preparations · Nasdaq · SEC CIK 1285819 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY181.2%
TTM EPS YoY176.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR70.1%

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA45.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets136.3%
Debt / equity—
Current ratio2.27x
Interest coverage-1.47x

Cash quality & payout

Operating cash flow / net income-0.38x
Accruals ratio62.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$35.93M$28.53M$9.89M—$0$0$0—
Cost of revenue$826,000$798,000$587,000—$0$0$0—
Gross profit$35.11M$27.73M$9.31M—$0$0$0—
R&D expense$16.06M$13.80M$13.36M$19.45M$15.99M$22.01M$23.85M$23.32M
SG&A expense$14.55M$13.86M$13.37M$9.63M$10.40M$10.35M$11.12M$12.34M
Operating income$4.50M$74,000-$17.42M-$29.08M-$26.39M-$32.35M-$34.97M-$35.66M
Interest expense$6.22M$7.58M$5.89M$8.73M-$13.36M$15,000$3.65M$3.18M
Pretax income-$63.78M$6.67M$51.31M$81.90M-$21.24M-$25.89M-$37.56M—
Income tax$46,000$29,000$57,000$2.01M$0$0$0—
Net income-$57.36M$13.23M$56.06M$86.45M-$30.92M-$25.42M-$33.46M-$31.36M
EBITDA$4.70M$274,000-$17.18M-$28.85M-$26.19M-$32.15M-$34.68M-$35.36M
EPS (basic)-0.790.180.78—-0.47-0.43-0.58—
EPS (diluted)-0.790.150.62—-0.47-0.43-0.58—
Weighted avg. shares (diluted)72.98M89.63M90.12M—66.26M58.59M58.06M—
Balance sheet
Cash & equivalents$5.07M$1.99M$1.91M$9.66M$2.40M$1.90M$4.26M$3.40M
Short-term investments$90.18M$129.97M$133.41M$162.14M$33.69M$26.84M$48.15M$86.73M
Receivables$16.10M$11.71M$6.75M$0$6.91M$6.28M$7.08M$7.74M
Inventory$453,000$842,000$183,000$0————
Current assets$150.89M$185.24M$180.35M$215.67M$71.81M$69.65M$96.18M$134.12M
PP&E, net$1.25M$1.38M$1.53M$1.77M$2.01M$2.24M$2.42M$2.68M
Total assets$248.09M$286.83M$286.17M$325.63M$185.71M$200.57M$235.16M$277.08M
Current liabilities$66.57M$94.96M$59.44M$78.06M$80.76M$85.50M$83.22M$79.53M
Long-term debt$31.89M$42.03M$52.81M$51.36M$154.94M$154.94M$164.94M$164.90M
Total debt$31.89M$42.03M$52.81M$51.36M$154.94M$154.94M$164.94M$164.90M
Total liabilities$338.07M$338.18M$349.51M$446.86M$406.18M$429.25M$448.71M$459.69M
Shareholders' equity-$89.97M-$51.35M-$63.33M-$121.23M-$220.48M-$228.69M-$213.55M-$182.61M
Net debt$26.82M$40.04M$50.90M$41.70M$152.54M$153.03M$160.68M$161.50M
Shares outstanding74.23M72.09M72.00M71.67M70.07M60.02M58.06M58.04M
Cash flow statement
Operating cash flow$13.26M$4.15M-$14.51M-$39.84M-$18.47M-$21.94M-$35.84M-$28.98M
Capital expenditure$25,000$45,000$0$0$11,000$13,000$41,000$26,000
Free cash flow$13.23M$4.10M-$14.51M-$39.84M-$18.48M-$21.95M-$35.88M-$29.01M
Investing cash flow$39.76M$3.40M$28.73M$111.55M-$6.86M$21.30M$38.54M$34.95M
Financing cash flow-$49.93M-$7.47M-$21.98M-$64.44M$25.82M-$1.72M-$1.84M-$4.09M
Depreciation & amortization$200,000$200,000$239,000$235,000$200,000$200,000$289,000$301,000
Stock-based compensation$3.00M$1.62M$1.89M$1.73M$1.94M$2.06M$2.45M$2.43M
Share buybacks$0$5.73M$4.15M$0$0$0$0$0

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.